Lexeo Therapeutics (LXEO) Return on Capital Employed (2023 - 2026)
Lexeo Therapeutics (LXEO) reported Return on Capital Employed of 39.86% for Q1 2026, up 7037.0% on a YoY basis from 0.56% in Q1 2025, and up 30.88% sequentially from 57.67% in Q4 2025.
Lexeo Therapeutics (LXEO) Return on Capital Employed (2023 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 4 years of Return on Capital Employed data on file, last reported at 39.86% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 7037.0% year-over-year to 39.86%; the trailing twelve-month figure through Mar 2026 stood at 39.86% (up 7037.0% YoY), and the FY2025 full-year result was 57.2%, up 3055.0% from the prior year.
- Return on Capital Employed advanced to 39.86% in Q1 2026, from 57.67% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 39.86% in Q1 2026 to a low of 110.23% in Q1 2025.
- A 4-year average of 70.46% and a median of 68.34% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 6341 bps in 2025 and jumped 7037 bps in 2026, its largest moves.
- Tracing LXEO's Return on Capital Employed over 4 years: stood at 85.61% in 2023, then increased by 10 bps to 76.89% in 2024, then grew by 25 bps to 57.67% in 2025, then soared by 31 bps to 39.86% in 2026.
- Business Quant data shows LXEO's Return on Capital Employed at 39.86% in Q1 2026, 57.67% in Q4 2025, and 79.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Lexeo Therapeutics | 379.94 Mn | 379.94 Mn | - | -39.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.86% |
| Dec 31, 2025 | -57.67% |
| Sep 30, 2025 | -79.56% |
| Jun 30, 2025 | -103.46% |
| Mar 31, 2025 | -110.23% |
| Dec 31, 2024 | -76.89% |
| Sep 30, 2024 | -59.80% |
| Jun 30, 2024 | -44.68% |
| Mar 31, 2024 | -46.82% |
| Dec 31, 2023 | -85.61% |